Topics:
Breast Cancer • Medical Oncology
Is there any role for additional chemotherapy for a pre-menopausal woman with locally advanced ER+, Her2- IDC, with residual disease after neoadjuvant AC?
Would you consider capecitabine in addition to paclitaxel?
Answer from: Medical Oncologist at Academic Institution
Locally advanced higher risk disease should get both AC and a taxane in either the neoadjuvant or adjuvant setting. So for ER+ disease I would give the taxane adjuvantly then move on to radiation and endocrine therapy in this case.
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
That there would be residual disease after Neoadjuvant chemotherapy is not a surprise due to the biology and the main strategy for long time cure and control is the endocrine therapy that follows.